BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3288807)

  • 1. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions.
    Croonen AM; van der Valk P; Herman CJ; Lindeman J
    Lab Invest; 1988 Jun; 58(6):725-32. PubMed ID: 3288807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
    Duggan MA; Masters CB; Alexander F
    Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mesothelial cell. Cytology. Cytochemistry. Immunocytochemistry. Contribution of immunolabelling to the cytodiagnosis of serous effusions with cells of mesothelial aspect].
    Marsan C; Gaulier A; Sabatier P; Garcia R
    Arch Anat Cytol Pathol; 1993; 41(5-6):223-8. PubMed ID: 8135583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M; Hoogsteden HC; Van der Kwast TH
    J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparameter flow cytometric DNA analysis of effusions: a prospective study of 36 cases compared with routine cytology and immunohistochemistry.
    Joseph MG; Banerjee D; Harris P; Gibson S; McFadden RG
    Mod Pathol; 1995 Aug; 8(6):686-93. PubMed ID: 8532707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of immunohistochemistry in clinical cytology].
    Weintraub D; Weintraub J; Vassilakos P
    Ann Pathol; 1987; 7(1):25-30. PubMed ID: 3304314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW; Koivurinne K
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
    Kobzik L; Antman KH; Warhol MJ
    Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
    Mezger J; Lamerz R; Permanetter W
    J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
    Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
    Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
    Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
    Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Image cytometry: an aid for cytological diagnosis of pleural effusions.
    Osterheld MC; Liette C; Anca M
    Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
    Granados R; Cibas ES; Fletcher JA
    Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.
    Frisman DM; McCarthy WF; Schleiff P; Buckner SB; Nocito JD; O'Leary TJ
    Mod Pathol; 1993 Mar; 6(2):179-84. PubMed ID: 8483888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA flow cytometry of pleural effusions. Comparison with pathology for the diagnosis of malignancy.
    Evans DA; Thornthwaite JT; Ng AB; Sugarbaker EV
    Anal Quant Cytol; 1983 Mar; 5(1):19-27. PubMed ID: 6846965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
    al-Saffar N; Hasleton PS
    Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.